
Innova Captab Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- The company expects to maintain a strong growth trajectory, aiming to double revenue and bottom-line over the next 3-4 years, driven primarily by the new Jammu facility.
- Jammu plant is projected to generate Rs 800-900 crores of sales in 3-4 years, with revenue start anticipated from Q3 FY25.
- The Jammu facility is expected to deliver better-than-Rs 200-300 crores revenue in FY25.
- Regular business (excluding Jammu) is expected to grow in the early teens percentage range due to capacity constraints.
- Overall blended growth for the current year is estimated between 12%-15%, with margins expected to remain at similar levels.
- Trade generics business aims to double within 3 years, maintaining its current ~17% share.
- Expansion of product categories and R&D investment supports long-term volume and revenue growth.
See what Innova Captab management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Innova Captab management said on order book — free account, 30 seconds.
Capex plans
Yes- The R&D capex for the new R&D center in Panchkula, Haryana, is already committed with an expenditure of Rs 10-15 crores expected this year.
- The Jammu facility's major capex is mostly completed with about Rs 450 crores invested so far.
- Future capex, apart from maintenance, will only be undertaken when planning for a new manufacturing facility; currently, maintenance capex is estimated at 3-4% of the gross block.
- The Jammu greenfield expansion is progressing as planned, expected to commercialize in Q2 FY25, with revenue starting from Q3 FY25.
- Jammu unit will have four independent manufacturing blocks, enhancing the product portfolio and capacity.
- Long-term, the Jammu plant has asset potential to generate up to Rs 2,000 crores in topline at 40-50% utilization, targeting Rs 800-900 crores in 3-4 years.
- No additional major capex is planned until the next facility is announced.
Track Innova Captab — get its next earnings analysis in your feed
How does Innova Captab rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Innova Captab rank in Pharmaceuticals & Biotechnology?
Compare Innova Captab against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Innova Captab's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem